Physician profile
Johnson Haynes, JR.
NPI 1760437800
$21,374.74
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,653 · 2020: $4,569 · 2021: $6,836 · 2022: $6,316.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $17,168.76 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $3,425.48 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $238.86 | 2019-2022 | |
| Astellas Pharma US INC | $93.99 | 2019-2021 | |
| Pfizer INC. | $83.35 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $82.87 | 2019-2020 | |
| Emmaus Medical, INC. | $38.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $38.10 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.55 | 2020-2021 | |
| Novo Nordisk INC | $32.27 | 2021 | |
| Sunovion Pharmaceuticals INC. | $28.60 | 2019 | |
| Philips North America LLC | $26.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $15.69 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.60 | 2020 | |
| Sanofi Pasteur INC. | $14.17 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13.97 | 2020 | |
| Sandoz INC. | $12.39 | 2021 | |
| Covidien LP | $11.92 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnson Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.